Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Shadfar Bahri

Showing results (31-40 of 33) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 33 results.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|July 17, 2021
Safety of PSMA-Targeted Molecular Radioligand Therapy with <sup>177</sup>Lu-PSMA-617: Results from the Prospective Multicenter Phase 2 Trial RESIST-PC (NCT03042312)Jeremie Calais, Johannes Czernin, Pan Thin, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|May 21, 2021
Prospective phase 2 trial of PSMA-targeted molecular RadiothErapy with <sup>177</sup>Lu-PSMA-617 for metastatic castration-reSISTant Prostate Cancer (RESIST-PC): efficacy results of the UCLA cohortJeremie Calais, Andrei Gafita, Matthias Eiber, et al.
JNCI Cancer Spectrum|July 23, 2025
Impact of postoperative fluorodeoxyglucose positron emission tomography/computed tomography on adjuvant head and neck cancer treatmentP Travis Courtney, Jesus E Juarez Casillas, Eulanca Y Liu, et al.
Pageof 4

Showing results (31-40 of 33) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 33 results.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|July 17, 2021
Safety of PSMA-Targeted Molecular Radioligand Therapy with <sup>177</sup>Lu-PSMA-617: Results from the Prospective Multicenter Phase 2 Trial RESIST-PC (NCT03042312)Jeremie Calais, Johannes Czernin, Pan Thin, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|May 21, 2021
Prospective phase 2 trial of PSMA-targeted molecular RadiothErapy with <sup>177</sup>Lu-PSMA-617 for metastatic castration-reSISTant Prostate Cancer (RESIST-PC): efficacy results of the UCLA cohortJeremie Calais, Andrei Gafita, Matthias Eiber, et al.
JNCI Cancer Spectrum|July 23, 2025
Impact of postoperative fluorodeoxyglucose positron emission tomography/computed tomography on adjuvant head and neck cancer treatmentP Travis Courtney, Jesus E Juarez Casillas, Eulanca Y Liu, et al.
Pageof 4